Acute Myeloid Leukemia Coverage From Every Angle
Advertisement
Advertisement

Revised Label Approved by FDA for Daunorubicin/Cytarabine Combination for AML

By: JNCCN 360 Staff
Posted: Friday, April 2, 2021

On March 30, the U.S. Food and Drug Administration (FDA) approved an updated label for the daunorubicin and cytarabine (Vyxeos) combination therapy to include a new indication for therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes in pediatric patients 1 year and older. The therapy is a liposomal combination of an anthracycline topoisomerase inhibitor and a nucleoside metabolic inhibitor. For more prescribing information visit accessdata.fda.gov.

The FDA approval for the new indication is based on safety and efficacy data from the phase 1/2 AAML1421 trial and the phase I CPX-MA-1201 clinical trial. Both studies enrolled patients with AML or relapsed/refractory hematologic malignancies. About 38 pediatric patients who were 21 years or older enrolled in the AAML1421 study, and 27 patients who were 1 to 19 years were enrolled in the CPX-MA-1201 study.

Clinical trial results from both studies found no differences in safety profile based on age. The indication is supported by evidence of effectiveness from the CPX351-301 trial in adult patients.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.